DTI 200
Alternative Names: DTI-200Latest Information Update: 28 Feb 2019
At a glance
- Originator Dignify Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase Unknown Bladder dysfunction; Gastrointestinal disorders
Most Recent Events
- 27 Feb 2019 DTI 200 is available for licensing as of 27 Feb 2019. https://dignifytherapeutics.com/
- 27 Feb 2019 Investigation in Bladder dysfunction in USA (unspecified route) prior to February 2019
- 27 Feb 2019 Investigation in Gastrointestinal disorders in USA (unspecified route) prior to February 2019